[1] Karnik S,Kanekar A.Childhood obesity:a global public health crisis[J].Int J Prev Med,2012,3(1):1-7.
[2] 李晓南.控制儿童青少年代谢综合征应从生命早期开始[J].中国儿童保健杂志,2013,22(5):456-458.
[3] Sacheck J.Pediatric obesity:an inflammatory condition?[J].J Parenter Enteral Nutr,2008,32(6):633-637.
[4] U.S.Department of Agriculture,U.S.Department of Health and Human Services.Dietary guidelines for Americans[M].7th ed.Washington,DC:US Government Printing Office,2010.
[5] Ortega FB,Tresaco B,Ruiz JR,et al.Cardiorespiratory fitness and sedentary activities are associated with adiposity in adolescents[J].Obesity (Silver Spring),2007,15(6):1589-1599.
[6] Osei-Assibey G,Dick S,Macdiarmid J,et al.The influence of the food environment on overweight and obesity in young children:a systematic review[J].BMJ Open,2012,2(6):e001538.
[7] Daniels SR,Greer FR.Lipid screening and cardiovascular health in childhood[J].Pediatrics,2008,122(1):198-208.
[8] Staels B,Fonseca VA.Bile acids and metabolic regulation:mechanisms and clinical responses to bile acid sequestration[J].Diabetes Care,2009,32(S2):237-245.
[9] Iughetti L,Bruzzi P,Predieri B.Evaluation and management of hyperlipidemia in children and adolescents[J].Curr Opin Pediatr,2010,22(4):485-493.
[10] Robbins DA.The safety and efficacy of statin therapy in the pediatric population[J].J Cardiovasc Nurs,2011,26(1):44-52.
[11] Mozaffarian D,Wu JHY.Omega-3 Fatty Acids and Cardiovascular Disease.Effects on risk factors,molecular pathways,and clinical events[J].JACC,2011,58(20):2047-2067.
[12] Siegel G,Ermilov E.Omega-3 fatty acids:benefits for cardio-cerebro-vascular diseases[J].Atherosclerosis,2012,225(2):291-295.
[13] Dujovne CA,Ettinger MP,McNeer JF,et al.Efficacy and safety of a potent new selective cholesterol absorption inhibitor,ezetimibe,in patients with primary hypercholesterolemia[J].Am J Cardiol,2002,90(10):1092-1097.
[14] 赵娟,杜军保.肥胖儿童青少年高血压早期诊断及干预对策[J].中国实用儿科杂志,2013,28(1):4-5.
[15] Nathan DM,Buse JB,Davidson MB,et al.Medical management of hyperglycemia in type 2 diabetes:a consensus algorithm for the initiation and adjustment of therapy a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes[J].Diabetes care,2009,32(1):193-203.
[16] Yki-Jrvinen H.Thiazolidinediones[J].N Engl J Med,2004,351(11):1106-1118.
[17] National Institutes of Health; National Heart,Lung and Blood Institute; North American Association for the Study of Obesity.The practical guide:identi-fication,evaluation,and treatment of overweight and obesity in adults[N].NIH Publication,2000,4000-4084.
[18] Chaput JP,St-Pierre S,Tremblay A.Currently available drugs for the treatment of obesity:sibutramine and orlistat[J].Mini Rev Med Chem,2007,7(1):3-10.
[19] Holick MF,Binkley NC,Bischoff-Ferrari HA,et al.Evaluation,treatment,and prevention of vitamin D deficiency:an endocrine society clinical practice guideline[J].Endocrine Society J Clin Endocrinol Metab,2011,96(7):1911-1930.
[20] Wolfgram PM,Carrel AL,Allen DB.Long-term effects of recombinant human growth hormone therapy in children with Prader-Willi syndrome[J].Curr Opin Pediatr,2013,25(4):509-514.
[21] O'Brien PE,Sawyer SM,Laurie C,et al.Laparoscopic adjustable gastric banding in severely obese adolescents:a randomized trial[J].JAMA,2010,303(6):519-526.
[22] Dixon JB,Zimmet P,Alberti KG,et al.Bariatric surgery:an IDF statement for obese type 2 diabetes[J].Diabet Med,2011,28(6):628-642. |
